LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Cerrado

SectorSanidad

3.57 -1.92

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.5300000000000002

Máximo

3.57

Métricas clave
By Trading Economics
Ingresos	-21M 41M
Ventas	59M 107M
P/B Media del Sector	6.726 51.415
BPA	0.24
Margen de beneficios	38.282
Empleados	100
EBITDA	64M 73M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+109.5% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-69M 686M
Apertura anterior	5.49
Cierre anterior	3.57

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

268 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

N/A / 0.9337 Soporte y Resistencia

Ironwood Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 may 2026, 23:53 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 may 2026, 23:50 UTC

Charlas de Mercado

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 may 2026, 23:36 UTC

Charlas de Mercado

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 may 2026, 23:07 UTC

Adquisiciones, fusiones, absorciones

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

UOB: Share Sale Agreements Entered With Singland Properties

17 may 2026, 23:05 UTC

Adquisiciones, fusiones, absorciones

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire Stake for $389 Million

17 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 may 2026, 16:27 UTC

Adquisiciones, fusiones, absorciones

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 may 2026, 15:26 UTC

Adquisiciones, fusiones, absorciones

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 may 2026, 08:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparación entre iguales

Cambio de precio

Ironwood Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

109.5% repunte

Estimación a 12 Meses

Media 7.5 USD 109.5%

Máximo 10 USD

Mínimo 5 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ironwood Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Ironwood Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 0.9337Soporte y Resistencia

Recent bearish events outweigh bullish events.

There are no events.

All events are bearish.

Sentimiento

By Acuity

268 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.